TD Cowen Remains a Buy on Alto Neuroscience, Inc. (ANRO)

TipRanks12minutes ago

Alto Neuroscience | 10-Q: Quarterly report

SEC announcementMay 14 15:38 · Announcements

Alto Neuroscience Q1 2024 Adj EPS $(0.76) Misses $(0.46) Estimate

Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.46) by 65.22 percent.

BenzingaMay 14 15:23

Alto Neuroscience Sees Cash Position to Support Planned Ops Into 2027 >ANRO

Alto Neuroscience Sees Cash Position to Support Planned Ops Into 2027 >ANRO

Dow JonesMay 14 15:12

Alto Neuroscience 1Q Loss/Shr 76c >ANRO

Alto Neuroscience 1Q Loss/Shr 76c >ANRO

Dow JonesMay 14 15:11

Press Release: Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights

Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights -- Initiated Phase 2 study of ALTO-203 in patients with MDD and anhedonia -- -- Reported positive Phase

Dow JonesMay 14 15:03